The National Institute for Health and Care Excellence chief executive has said that the pharmaceutical industry should disclose more data from clinical trials.
Sir Andrew Dillon said: “I would like to see more data transparency… in order to improve our relationship with the industry.”
He said it would be “great” if companies can “achieve” the step of releasing the evaluation information “before a [drug] goes into the market”.
The industry has faced calls from campaigners, patient groups, politicians and others in recent years to make more information available.
Sir Andrew said the health sector also had a role to play in making more information available about drugs’ effect.
He called for “a joint effort to make it possible for us to understand what is happening to drugs inside the system once the products are in routine use - it would be great”.
“Our systems have to want to put the effort into collecting clinical data as much as they put an effort into collecting billions of data items on the financing of the system, which we do rather well,” Sir Andrew said.
He was speaking on a panel at the Economist Pharma Summit in London last week.
No comments yet